Keyphrases
Placebo
83%
In-hospital Cardiac Arrest
66%
Randomized Clinical Trial
66%
Age of Onset
66%
Time Duration
66%
Vasopressin
66%
Methylprednisolone
66%
Intubation Conditions
66%
Duration of Action
66%
Coronavirus Disease (COVID)
66%
COVID-19
58%
Number of Days
50%
Days Alive without Life Support
50%
Patients with COVID-19
46%
Randomized Placebo-controlled Trial
44%
Placebo Groups
42%
Elderly Patients
36%
Rocuronium
33%
Return of Spontaneous Circulation
33%
Transcutaneous Carbon Dioxide Monitoring
33%
Randomized Trial
33%
Young Patients
33%
Cisatracurium
33%
Severe Hypoxemia
33%
Severe Hypoxia
33%
Prolonged Apnea
33%
Low-dose Hydrocortisone
33%
Apneic Oxygenation
33%
High-flow Nasal Oxygen
33%
Intervention Group
30%
Risk Ratio
25%
Hydrocortisone
25%
Epinephrine
21%
Serious Adverse Reaction
21%
Adjusted Relative Risk
20%
Train-of-four Count
18%
Hypercapnia
16%
Carbon Dioxide Levels
16%
Arterial Carbon Dioxide Tension
16%
Corticosteroids
16%
Difficulty Index
15%
Neurological Outcome
15%
First Dose
15%
Adjusted Means
15%
Mechanical Ventilation
15%
Health-related Quality of Life
13%
Intravenous Dexamethasone
13%
Neurological Health
13%
Favorable Neurological Outcome
13%
Risk Difference
12%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Randomized Clinical Trial
68%
Heart Arrest
66%
Methylprednisolone
66%
Vasopressin
66%
Rocuronium
33%
Hypoxia
33%
Hypoxemia
33%
Dexamethasone
33%
Apnea
33%
Hydrocortisone
33%
Carbon Dioxide
33%
Epinephrine
19%
Clinical Trial
13%
Adverse Event
10%
Hypercapnia
8%
Methylprednisolone Sodium Succinate
6%
Drug Screening
6%
Medicine and Dentistry
Placebo
66%
Return of Spontaneous Circulation
33%
Heart Arrest
33%
Vasopressin
33%
Hypoxia
33%
Hydrocortisone
33%
COVID-19
33%
Transcutaneous Carbon Dioxide Monitoring
33%
Elderly Patient
33%
Methylprednisolone
33%
Cisatracurium
33%
Low Drug Dose
33%
Randomized Clinical Trial
33%
Apnea
33%
Carbon Dioxide
33%
Hypercapnia
12%
Clinical Trial
11%
Hoarseness
9%
Propofol
9%
Attributable Risk
9%
Epinephrine
6%
Artificial Respiration
5%
Adverse Event
5%
